The laws of the universe are indisputable. As we know from Darwinian evolution, it is not the strongest or the smartest that survive.
It is the most adaptable.
To be adaptable, you need to react to your environment. Over the past 12 months, the regenerative medicine (RM) industry has dramatically changed and expanded. Some companies are thriving, while others are going out of business or being acquired by the competition.
Companies like MAGiQ Therapeutics
(a collaboration between Q Therapeutics and Reprocell to develop stem cell therapies for ALS) and Scout Bio
(a gene therapy spin-out from Penn Medical School operating in stealth mode) have entered the marketplace. Others, like Precious Cells International, have gone out of business.
Merger and acquisition (M&A) activity is also reaching new heights, most notably within the CAR-T cell space. Celgene snagged Juno Therapeutics for a shocking $9 billion in January 2018. Gilead acquired Kite Pharma for an astounding $11.9 billion in August 2017. Most recently, Takeda Pharmaceuticals made an astonishing offer to acquire Shire for $64 billion in April 2018.